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Multiple sclerosis (MS) has traditionally been considered an autoimmune inflammatory
disorder leading to demyelination and clinical debilitation as evidenced by our current
standard anti-inflammatory and immunosuppressive treatment regimens. While these
approaches do control the frequency of clinical relapses, they do not prevent the
progressive functional decline that plagues many people with MS. Many avenues of
research indicate that a neurodegenerative process may also play a significant role in
MS from the early stages of disease, and one of the current hypotheses identifies
mitochondrial dysfunction as a key contributing mechanism. We have hypothesized that
pathological permeability transition pore (PTP) opening mediated by reactive oxygen
species (ROS) and calcium dysregulation is central to mitochondrial dysfunction and
neurodegeneration in MS. This focused review highlights recent evidence supporting
this hypothesis, with particular emphasis on our in vitro and in vivo work with the
mitochondria-targeted redox enzyme p66ShcA.
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MULTIPLE SCLEROSIS AS A
NEURODEGENERATIVE DISORDER
Multiple sclerosis (MS) is one of the most com-
mon neurological diseases plaguing more than
2.1 million people worldwide. About 85% of
patients present with a relapsing-remitting phe-
notype during which they experience clinical
attacks, or relapses, causing neurological dys-
function including optic neuritis and transverse
myelitis. About 50% of these patients eventually
transition into a secondary progressive pheno-
type characterized by continuously worsening
neurological function leading to significant per-
manent disability. About 15% of patients have
disease that is progressive from onset, referred
to as primary progressive MS (Noseworthy et al.,
2000).
Traditionally, MS has been considered
an autoimmune disorder in which T cells,
macrophages, soluble mediators of inflam-
mation, and autoantibodies contribute to
multifocal demyelination. Currently available
treatment options, which include interferon-
beta, glatiramer acetate, natalizumab, and
fingolimod, are designed to control the
pathogenic inflammatory processes through
varying mechanisms. While these medications
have proven to be beneficial in limiting the
frequency of acute relapses in MS patients, they
are minimally effective in preventing the pro-
gressive neurological decline that contributes
largely to long-term disability in people with
MS. Consequently, it is now clear that the
disease is much more complex and not purely
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an autoimmune disease driven by the adaptive
arm of the immune system. Besides the appear-
ance of episodic focal inflammation lesions,
there is a more generalized and progressive
disease process that results in slow axonal and
neuronal degeneration. The pathogenesis of
this neurodegenerative process is uncertain. It
may be driven by release of ROS by activated
microglia or by axoplasmic accumulation of
Ca2+ resulting for ionic imbalances within
chronically demyelinated axons. Therefore, it is
likely that other mechanisms are involved in MS
disease pathophysiology and hence need to be
Multiple sclerosis
Multiple sclerosis (MS) is one of the
most common neurological diseases
afflicting more than 2.1 million people
worldwide. Of unknown etiology,
classically MS has been considered an
inflammatory disease in which both
cellular and soluble mediators of
inflammation result in multifocal
demyelination. Thus, much effort has
gone into developing therapies to
control the pernicious immune
response in MS. Over the past decade,
however, the importance of axonal
injury in MS has gained increasing
attention and is now recognized as
critical to the irreversible disability that
occurs in this disease.
Neurodegeneration
Neurodegeneration is the umbrella
term for the progressive loss of
structure or function of neurons,
including death of neurons and
breakage or severing of axons. Many
neurodegenerative diseases including
Parkinson’s, Alzheimer’s, Amyotrophic
lateral sclerosis, Huntington’s and more
recently MS occur as a result of
neurodegenerative processes. As
research progresses, many similarities
appear which relate these diseases to
one another on a sub-cellular level and
in all cases, mitochondrial dysfunction
has been proposed to play a critical
role.
Mitochondrial dysfunction
The most common form of cell death
in neurodegeneration is through
various mitochondrial pathways. These
pathways can control the activation of
caspase-9 by regulating the release of
cytochrome c from the mitochondrial
intermembrane space (IMS). In
addition, reactive oxygen species (ROS)
are normal byproducts of
mitochondrial respiratory chain
activity. Over production of ROS
(oxidative stress) is a central feature of
all neurodegenerative disorders.
Mitochondria are also involved with
life-sustaining functions including
calcium homeostasis, PCD,
mitochondrial fission and fusion, lipid
concentration of the mitochondrial
membranes, and the mitochondrial
permeability transition. Mitochondrial
disease leading to neurodegeneration is
likely, at least on some level, to involve
all of these functions.
addressed.
Of note, the famous neurologist Jean Martin
Charcot mentioned in his early descriptions of
MS that axonal pathology may play a role in
the disease. However, given technological limi-
tations, it was not until more recently with the
development of advanced in vivo and in vitro
imaging techniques that there was solid evi-
dence that neurodegeneration occurs early in
both gray and white matter of MS patients
(Lovas et al., 2000; Kuhlmann et al., 2002;
Ingle et al., 2003; Kutzelnigg et al., 2005;
Herrero-Herranz et al., 2008). For example,
immunohistochemistry, confocal imaging, and
3-D computer reconstruction of post-mortem
MS patient brains showed a significant amount
of transected axons in both active and chronic
active white matter lesions (Trapp et al., 1998).
In addition, axonal degeneration analysis in
chronic inactive lesions of secondary progressive
MS patient spinal cords using similar methods
indicated a 61% reduction in axonal density
(Bjartmar et al., 2003). Likewise, analysis of nor-
mal appearing white matter (NAWM) showed
decreased nerve fiber densities in patient spinal
cords (Bjartmar et al., 2001). These postmortem
results have been confirmed by in vivo stud-
ies utilizing magnetic resonance spectrometry
(MRS), which determines the chemical com-
position of brain matter via analysis of certain
peaks in the resonance spectra. In particular,
the metabolite N-acetyaspartate (NAA) pro-
duced by neuronal mitochondria is considered
an important monitor of neuronal integrity,
and decreases in NAA have been correlated
with relapses and neurological decline in MS
patients (Fu et al., 1998; Signoretti et al., 2001;
Lu et al., 2004; Benarroch, 2008). Furthermore,
NAA levels are decreased in MS white mat-
ter lesions and NAWM as well as gray mat-
ter, suggesting that neurodegenerative processes
are widespread throughout the central nervous
system (CNS). Interestingly, gray matter atro-
phy rates have been correlated with worsening
disability as shown by a 3.4-fold increase in
atrophy from clinically isolated syndromes to
relapsing remitting MS, and a 14-fold increase in
atrophy from relapsing-remitting to secondary
progressive MS. In contrast, white matter atro-
phy rates were constant at 3-fold across the MS
stages (Fisher et al., 2008).
MITOCHONDRIAL DYSFUNCTION AND
NEURODEGENERATION IN MS
One of the mechanisms hypothesized to explain
the diffuse neurodegeneration found in MS
patients involves mitochondrial dysfunction.
Mitochondria are essential intracellular
organelles involved in ATP synthesis and
calcium regulation and are also major sources
of reactive oxygen species (ROS). Therefore,
diffuse mitochondrial dysfunction secondary
to MS disease processes could lead to inad-
equate energy production and intracellular
dysregulation. This dysfunction is particu-
larly damaging to neurons given their unique
elongated morphology and dependence on
ATP to propagate electrical signals, maintain
ionic gradients, and facilitate anterograde and
retrograde transportation along axons.
There is accumulating in vitro and in vivo
evidence of mitochondrial dysfunction in MS.
For one, NAA, the commonly used MRSmarker
of neuronal integrity, is produced by neuronal
mitochondria. Therefore, changes in NAA lev-
els can also reflect mitochondrial dysfunction
within neurons (Fu et al., 1998; Signoretti et al.,
2001; Benarroch, 2008). As previously men-
tioned, changes in NAA levels correspond with
relapses and have been shown to fall dra-
matically in acute inflammatory lesions and
partially reverse as inflammation subsides (Fu
et al., 1998; Khan et al., 2005). The initial
dramatic decline in NAA undoubtedly reflects
reversible mitochondrial dysfunction in neu-
rons within these acute lesions. Similar NAA
decreases in chronic focal white matter lesions
and NAWM also may suggest chronic mito-
chondrial dysfunction within neurons as well as
neuronal loss (Bjartmar et al., 2000). In addi-
tion, evidence linking mitochondrial dysfunc-
tion to neurodegeneration has been shown by
post-mortem analysis ofMS patient brain tissue,
including lesioned areas, NAWM, and nonle-
sional cortex. Structurally, electron microscopy
of demyelinated spinal cord lesions show dra-
matically decreased numbers of mitochondria
and microtubules (Dutta et al., 2006). Further
analysis indicates oxidative damage of mito-
chondrial DNA and impaired activity of mito-
chondrial enzyme complexes in lesioned tissue
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(Lu et al., 2000), and reduced mitochondrial
gene expression specific to neurons in nonle-
sional tissue (Dutta et al., 2006). Finally, there is
compelling evidence of mitochondrial dysfunc-
tion from in vivo imaging of double-transgenic
mice with CFP-labeled mitochondria and YFP-
labeled axoplasm (Thy1-MitoCFP × Thy1-YFP-
16) induced with experimental autoimmune
encephalomyelitis (EAE), a commonly used ani-
mal model for MS (Nikic et al., 2011). In
monitoring single axons in the EAE-induced
animals, abnormal mitochondrial morphology
was noted to be the earliest ultrastructural
sign of damage, preceding structural changes.
Subsequent analysis of active lesions in MS
patient biopsies showed similar mitochondrial
damage in both structurally intact and demyeli-
nating axons. Overall, these multifaceted studies
provide convincing evidence that mitochondrial
function may play a significant role in MS neu-
rodegenerative mechanisms.
MITOCHONDRIAL DYSFUNCTION AND THE
PERMEABILITY TRANSITION PORE (PTP)
We have proposed that mitochondrial dysfunc-
Reactive oxygen species
Reactive oxygen species (ROS) are
potent intracellular oxidants that
include hydrogen peroxide, superoxide,
and hydroxyl radicals. They are
commonly produced by dedicated
enzymes, the NADPH oxidases, and as
metabolic byproducts due to electron
leaks by the electron transport chain.
Because of their potential damaging
effects on cellular macromolecules such
as nucleic acids, proteins, and lipids,
ROS levels are tightly regulated by
intracellular superoxide dismutases and
catalases. However, various stressors
can dramatically increase ROS levels
leading to significant intracellular
damage. This is especially true for
mitochondria, which are major sites of
ROS production due to aerobic
respiration and oxidative
phosphorylation. ROS are potent
activators of the mitochondrial
permeability transition.
Mitochondrial permeability
transition pore
The ability of mitochondria to take up
and release calcium (Ca2+) is well
established and the response of
mitochondria to the addition of Ca2+
depends on the amount of Ca2+ added
and the level of matrix Ca2+. If
sufficient Ca2+ is accumulated within
the mitochondrial matrix, a large
increase in permeability of the inner
mitochondrial membrane is induced
with the loss of solutes with a
molecular weight less than 1.5 kDa.
This phenomenon is termed the
mitochondrial permeability transition
pore (PTP). In an isolated
mitochondria preparation, opening of
the PTP leads to swelling of the
mitochondria, which is commonly used
as a measure of PTP opening. However,
although mitochondrial swelling occurs
with isolated mitochondria undergoing
PTP, mitochondrial swelling does not
appear to occur in situ because of the
high cytosolic level of proteins and
solutes. In addition to Ca2+ , opening of
the PTP is triggered by ROS. The PTP
has been implicated as playing a key
role in apoptotic and necrotic cell
death.
tion in MS may be mediated by the patholog-
ical opening of the mitochondrial permeabil-
ity transition pore (PTP). The PTP is a tran-
sient pore located in the inner mitochondrial
membrane that when open allows solutes with
molecular masses up to 1500 Daltons to enter.
The pore transiently opens to certain stimuli,
including calcium, reactive oxygen and nitrogen
species. Persistent pathological pore opening
induces the influx of solutes into the mitochon-
drial matrix resulting in loss of the mitochon-
drial membrane potential and equilibrium of
ionic gradients, which can prevent ATP synthe-
sis, and promote matrix expansion, mitochon-
drial swelling, andmembrane rupture leading to
release of cytochrome c into the cytoplasm and
eventual cell death (Bernardi et al., 2006).
CYCLOPHILIN D AND THE PTP
Cyclophilin D (CyPD), a mitochondrial matrix
protein, plays a crucial regulatory role in PTP
opening. Various pharmacologic and genetic
techniques have been used to alter CyPD activity
and expression, including cyclosporin A (CsA)
administration, which inhibits CyPD, and dele-
tion of the murine Ppif gene, which encodes
CyPD. CsA treatment has long been shown
to inhibit PTP opening, and has been tested
in several ex vivo and in vivo models of dis-
ease, including ischemic-reperfusion injury of
the heart, and ischemic and traumatic brain
injury (Griffiths and Halestrap, 1993; Friberg
et al., 1998). In particular, CsA pre-treatment
of insulin-induced hypoglycemic mice has been
shown to significantly reduce brain damage, and
ultrastructural examination suggests that the
marked protection is due in part to mitochon-
drial preservation. Alteration of CyPD activity
by Ppif gene deletion (CyPD-knockout; CyPD-
KO) has resulted in viable animals that still
can form the PTP but have a higher mito-
chondrial Ca2+ set point for PTP activation.
Consequently, the mitochondria in CyPD-KO
mice are able to retain about double the amount
of Ca2+ as mitochondria from wild-type (WT)
animals before PTP activation, demonstrating
that CyPD is a significant regulator of PTP
opening (Baines et al., 2005; Basso et al., 2005).
Due to the altered PTP properties in CyPD-
KO mice, they have been used in stud-
ies addressing mitochondria dysfunction and
disease pathology. For instance, CyPD-KO
mice subjected to cardiac ischemia/reperfusion
showed a 40% reduction in myocardial infarc-
tion compared to WT mice (Baines et al., 2005).
Similarly, Schinzel et al. found that CyPD-KO
mice were significantly protected from brain
ischemia/reperfusion injury via middle cerebral
artery occlusion, demonstrating a 62% reduc-
tion in brain infarct size (Schinzel et al., 2005).
These findings suggest that CyPD elimination
and ensuing alteration of PTP properties gen-
erates significant protection in various disease
models and organ systems.
To address the mitochondrial hypothesis of
neurodegeneration in MS, CyPD-KO mice were
induced with EAE (Forte et al., 2007). EAE
is a well-recognized animal model for MS,
and involves immunization with fragments of
myelin proteins, including myelin oligodendro-
cyte glycoprotein (MOG) and proteolipopro-
tein (PLP). In this study, C57BL/6 background
CyPD-KO and WT mice were immunized with
MOG 35-55 peptide to induce EAE. The immu-
nized CyPD-KO mice developed clinical signs
of hindlimb and forelimb weakness and paraly-
sis, but unlike the WT mice, partially recovered.
Histologic analysis of CyPD-KO spinal cords
showed significantly decreased axonal damage
and loss compared to WT cords despite hav-
ing similar levels of CD4+ T cells and CD11b+
macrophages/microglia. Furthermore, isolated
CyPD-KO neurons were more resistant to treat-
ment with H2O2 and NO, and CyPD-KO brain
mitochondria were able to sequester substan-
tially greater amounts of Ca2+. These results
indicate that regulation of PTP opening and
mitochondria integrity has a significant effect
on EAE disease progression and axonal survival.
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REACTIVE OXYGEN SPECIES AND THE PTP
Further study of mitochondrial dysfunction in
the context of the PTP has led to the investi-
gation of critical upstream promoters of PTP
opening, including ROS (Bernardi et al., 2006).
In terms of ROS, these are potent intracellu-
lar oxidants that include hydrogen peroxide,
superoxide, and hydroxyl radicals. They are
commonly produced by dedicated enzymes, the
NADPH oxidases, and as metabolic byprod-
ucts due to electron leaks by the electron
transport chain (Esposito et al., 1999; Turrens,
2003; Bedard et al., 2007). Because of their
potential damaging effects on cellular macro-
molecules such as nucleic acids, proteins, and
lipids, ROS levels are tightly regulated by
intracellular superoxide dismutases and cata-
lases. However, various stressors can dramati-
cally increase ROS levels leading to significant
intracellular damage. This is especially true
for mitochondria, which are major sites of
ROS production due to aerobic respiration and
oxidative phosphorylation.
Recently, yet another pathway for mito-
chondrial ROS production has been discovered
involving the p66ShcA (p66) protein (Giorgio
et al., 2005; Hajnóczky and Hoek, 2007; Pinton
et al., 2007). The ShcA gene encodes two
mRNA species, one specific for p66 and one,
by the use of alternate translation start sites,
encoding the p46 and p52 isoforms (Migliaccio
et al., 1999). While all three isoforms share
the same amino acid sequence at the C termi-
nus, including phosphotyrosine-binding (PTB),
p66ShcA
The ShcA gene encodes two mRNA
species, one specific for p66 and one, by
the use of alternate translation start
sites, encoding the p46 and p52
isoforms. While all three isoforms share
the same amino acid sequence at the C
terminus, including
phosphotyrosine-binding (PTB), Src
homology 2 (SH2), and collagen
homology (CH1) domains, only the
p66 isoform has a unique N terminus
that allows it to be serine
phosphorylated and targeted to
mitochondria. Consequently, in
contrast to p46 and p52, p66 is not
involved in the transmission of
activation signals from receptor
tyrosine kinases to Ras proteins. Rather,
the p66 isoform gets serine
phosphorylated in the cytoplasm and
subsequently targets to the
mitochondrial intermembrane space.
There, it serves as a redox enzyme by
oxidizing cytochrome c, and
transferring electrons to reduce oxygen
into superoxide and hydrogen peroxide
This localized pool of mitochondrial
ROS mediates PTP opening and cell
death activation.
Src homology 2 (SH2), and collagen homol-
ogy (CH1) domains, only the p66 isoform has
a unique N terminus that allows it to be serine
phosphorylated and targeted to mitochondria.
Consequently, in contrast to p46 and p52, p66
is not involved in the transmission of activa-
tion signals from receptor tyrosine kinases to
Ras proteins (Migliaccio et al., 1997). Rather, the
p66 isoform gets serine phosphorylated by pro-
tein kinase C-Beta (PKC-β) in the cytoplasm,
and following interaction with isomerase Pin1,
subsequently targets to the mitochondrial inter-
membrane space. There, it serves as a redox
enzyme by oxidizing cytochrome c, and trans-
ferring electrons to reduce oxygen into superox-
ide and hydrogen peroxide (Giorgio et al., 2005).
This localized pool ofmitochondrial ROS is pro-
posed to mediate PTP opening and cell death
activation.
Furthermore, p66 is part of a posi-
tive feed-forward signaling pathway for
mitochondria-mediated cell death, serving as
both a ROS sensor and amplifier (Figure 1).
At typical cellular conditions, cytoplasmic
p66 is unphosphorylated, and according to
various studies in mitochondrial preparations,
is sequestered in a ROS stress-sensing complex
that keeps p66 inactive at low to moderate stress
levels. In particular, peroxiredoxin (Prx) 1 has
been proposed to be part of this complex (Gertz
et al., 2009). Prxs are a family of thiol-based
H2O2-degrading enzymes, so-called peroxi-
dases, and are weak scavengers with the ability
to degrade low levels of cellular H2O2. At these
conditions, the stress-sensing complex consists
of Prx1 in its dimerized, active form, and p66
in its dimerized, inactive form. However, at
elevated levels of cellular stress, Prx1 function
becomes overwhelmed, and the Prx1/p66 com-
plex disassembles, freeing up p66 for activation.
In addition, it has been shown that upon induc-
tion by stress factors, p66 expression increases
and existing p66 becomes stabilized, further
amplifying the pool of cytosolic p66 available
for serine phosphorylation by stress activated
PKC-β. Phosphorylated p66 translocates into
the mitochondrial intermembrane space fol-
lowing interaction with Pin1 isomerase, and
there, it serves as a ROS amplifier by generating
mitochondrial ROS to induce PTP opening,
which further elevates oxidative stress levels and
activates mitochondria-mediated cell death.
Efforts to analyze the potential protec-
tive effects of p66 elimination have led to
in vitro and in vivo studies of p66 elimination
by genetic manipulation. For instance, p66-
knockout (p66-KO) mouse embryonic fibrob-
lasts (MEFs) were found to have increased
resistance to H2O2 treatment compared to
WT MEFs, and notably, this greater viability
could be significantly reduced via retroviral-
induced p66 expression (Migliaccio et al., 1999).
Furthermore, assessment of mitochondria mor-
phology in the stressed MEFs showed that p66-
KO MEF mitochondria remained intact and
elongated following H2O2 treatment compared
to the noticeably swollen and fragmented WT
MEF mitochondria (Pinton et al., 2007). In
the in vivo setting, p66-KO mice were also
more resistant to oxidative stress as indicated
by their response to paraquat treatment, which
induces superoxide production upon cellular
intake. Treated p66-KOmice had a 40% increase
in mean survival time compared to WT mice
(Migliaccio et al., 1999). It is likely due to such
protective effects that p66-KO mice have signif-
icantly prolonged lifespans, around 30% longer
than those of WT mice, leading to the idea that
p66 is a longevity gene. However, more recent
studies have indicated that the longer life span
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FIGURE 1 | Model of p66ShcA-mediated feed forward pathway of
mitochondrial ROS and neurodegeneration in MS. Under normal
cellular conditions, p66ShcA is sequestered by Prx1 in an inactive form.
Under the excessive cellular stressors associated with MS disease
processes, p66ShcA is disassociated from Prx1 and is serine
phosphorylated by PKC-β. Phosphorylated p66ShcA forms a complex
with Pin1 isomerase, which leads to p66ShcA translocation into the
intermitochondrial space (IMS). There, p66ShcA oxidizes cytochrome c
and reduces oxygen to form mitochondrial ROS, which induces opening
of the mitochondrial PTP. PTP opening subsequently induces the influx
of solutes into the mitochondrial matrix resulting in loss of
mitochondrial membrane potential and equilibrium of ionic gradients,
which can prevent ATP synthesis, and promote matrix expansion,
mitochondrial swelling, and membrane rupture leading to release of
cytochrome c into the axoplasm and eventual neuronal death.
Importantly, p66ShcA is part of a positive feed-forward signaling
pathway that further elevates oxidative stress levels and activates
mitochondria-mediated neuronal death.
of the mice can only be observed in protected
laboratory conditions (Giorgio et al., 2012).
In the context of human disease, p66 elimina-
tion has been shown to be protective in various
disease models and organ systems. In partic-
ular, p66-KO mice maintained on a chronic
21% high fat diet had significantly decreased
aortic cumulative early lesion area compared
to WT mice (21% in WT; 3% in p66-KO),
and immunohistochemical analysis showed less
macrophage-derived foam cells and apoptotic
vascular cells in the p66-KO lesions (Napoli
et al., 2003). Similarly, p66-KO mice used in
a diabetes disease model demonstrated less
marked changes in renal structure and func-
tion as evidenced by significantly lower levels
of proteinuria, albuminuria, glomerular sclero-
sis index, and glomerular and mesangial areas,
as well as decreased apoptotic cell death (Menini
et al., 2006). Recent studies have shown however
that in response to the elimination of p66 in this
KO line, another Shc isoform, p46 has a four-
fold increased expression in white fat (Tamilov
et al., 2011). As a result, it has been suggested the
p46 overexpression in white fat, rather than p66-
KO, is might be the cause of decreased adipos-
ity and reduced insulin-sensitivity in the fat of
p66-KO mice. The protective effects of p66 also
extended to other diseases including ethanol-
induced liver damage, in which p66-KO mice
fed with an alcohol-rich diet showed reduced
liver swelling, serum ALT levels and attenuated
fatty changes compared to WT controls (Koch
et al., 2008).
We utilized these p66-KO mice to inves-
tigate whether altering mitochondrial ROS
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production might be neuroprotective in the
context of EAE (Su et al., 2012a). Similar to
the aforementioned experiments on CyPD-KO
mice, the p66-KO mice were induced with
EAE by MOG 35-55 peptide immunization and
monitored for clinical signs of hindlimb and
forelimb weakness and paralysis over a 36-day
period. Overall, clinical protection was observed
in the p66-KO mice compared to WT mice fol-
lowing EAE induction. Throughout the entire
observation period, the p66-KO mice had con-
sistently lower mean EAE scores compared to
the WT mice. Furthermore, the p66-KO mice
had significantly lower mean EAE scores at the
end of the observation period, reflecting the
consistent trend of reduced clinical impairment
with p66 elimination.
Following the 36-day observation period,
spinal cords and optic nerves were processed for
histological analysis via plastic embedding and
toluidine blue staining. Sections were manually
quantified for pathological changes, including
swollen axons, degenerating axons, demyeli-
nated axons, irregularly myelinated axons,
myelin oviods, microcysts, and areas devoid of
axons. Results indicated significant protection
in both optic nerves and spinal cord sections
of the p66-KO mice with EAE compared to
WT controls, roughly 38 and 42% decreases in
neuronal pathology, respectively. Furthermore,
immunohistochemical analysis of immune cell
infiltration within the p66-KO and WT tis-
sue showed that the neuroprotection observed
with p66 elimination was not attributable to a
reduced inflammatory response following EAE
induction. Specifically, CD4 and CD11b stain-
ing for T cells and macrophages were simi-
lar between the p66-KO and WT mice with
EAE. Similar responses were also noted for pro-
liferation assays and cytokine profiling with
MOG 35-55 peptide stimulation. Overall, these
results suggest that the neuroprotective effects
of p66 elimination were not attributable to
altered MOG 35-55 peptide immunoreactivity
and reduced CNS inflammation with EAE.
We next investigated the neuroprotective
effects of p66 elimination at an in vitro, sub-
cellular level by manipulating hippocampal
neuronal cultures of p66-KO and WT mice
(Su et al., 2012b). Briefly, hippocampal cul-
tures were treated with varying concentrations
of H2O2 and nitric oxide donor diethylene-
triamine/nitric oxide adduct (DETA-NO) and
assessed for neuronal viability and changes
in mitochondrial structure and function. As
expected, greater cell viability was demon-
strated in the p66-KO cultures compared to WT
cultures at the various treatment concentrations
of H2O2 and DETA-NO. In terms of mito-
chondrial structure and function, changes in
mitochondrial morphology and mitochondria-
localized ROS were examined. Previous studies
have shown that morphology changes correlate
with eventual neuronal damage under various
noxious conditions associated with neurodegen-
erative diseases (Solenski et al., 2002; Nikic et al.,
2011). Mitochondria, which are normally thin
and elongated in morphology, become swollen
and fragmented prior to notable structural
damage of axons, and therefore may serve as a
key marker of neuronal distress. Furthermore,
increased intracellular production of oxidative
agents, in particular, mitochondria-localized
ROS, has been shown to exacerbate neuronal
distress in multiple neurodegenerative disease
models (Fiskum et al., 2003; Scherz-Shouval and
Elazar, 2007). The results from the p66-KO and
WT studies demonstrated that mitochondrial
morphology changes were less prominent in the
p66-KO neurons compared to the WT neurons,
with significantly greater preservation of mito-
chondrial length following treatment with either
H2O2 or DETA-NO. In addition, the p66-KO
neurons exhibited less elevated mitochondrial
ROS levels compared to WT neurons following
oxidative insults. Overall, the results suggest that
p66 elimination incurs greater neuronal robust-
ness and preservation of mitochondrial integrity
following oxidative insults implicated in EAE-
and MS-associated degenerative mechanisms.
Importantly, these findings support our cur-
rent understanding of p66 and its role in cel-
lular responses to oxidative challenges. As out-
lined earlier, p66 is thought to serve as a ROS
sensor and amplifier under conditions of cel-
lular stress by amplifying ROS generation via
cytochrome c oxidation and oxygen reduction
(Giorgio et al., 2005). Subsequently, elevated
ROS has been shown to induce PTP open-
ing as demonstrated by mitochondrial swelling,
rupture, and release of cytochrome c to acti-
vate apoptotic pathways (Petronilli et al., 1994;
Vercesi et al., 1997; Yang et al., 2007). The
results reported here are consistent with this
proposed pathway, as shown by the higher ROS
levels in WT neurons compared to p66-KO neu-
rons following stresses induced by H2O2 or
DETA-NO treatment, demonstrating that p66
elimination reduces ROS amplification follow-
ing these insults. This, in turn, provides greater
preservation of mitochondrial integrity as visu-
alized by mitochondrial morphology. Previous
studies have correlated changes in mitochon-
drial morphology with mitochondrial integrity
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and activity, including the balance of fission
and fusion events and mitophagy of dam-
aged mitochondria. In particular, it has been
shown that the dissipation of the mitochon-
drial membrane potential affects fusion and
induces mitochondrial fragmentation (Legros
et al., 2002). Furthermore, mitochondrial mor-
phology changes may be correlated to matrix
swelling mediated by pathologic PTP open-
ing, release of cytochrome c, and activation
of cell death pathways (Scorrano et al., 2002).
Assuming that p66 elimination alters the cell
crisis signal of elevated mitochondrial ROS,
preserves mitochondrial integrity, and subse-
quently regulates PTP-mediated cell death, this
would suggest greater neuronal robustness in
p66-KO neurons following these stresses, as is
supported by the cell viability studies.
INDICATIONS FOR
MITOCHONDRIA-TARGETED
NEUROPROTECTIVE TREATMENTS
Overall, the characterization of p66 elimination
in neurons supports previous studies demon-
strating mitochondrial integrity as a key marker
of neuronal viability and fate (Nikic et al.,
2011). Hence, therapeutics promoting mito-
chondrial preservation may prove essential to
current treatment regimens for neurodegen-
erative diseases including MS. Mitochondria-
directed therapies are still in their infancy,
largely limited to in vitro and in vivo ani-
mal studies to test their properties and efficacy,
though a few are now being investigated in
human clinical trials. They span a wide range
of mitochondria-specific targets including the
electron transport chain, ATP synthase, mito-
chondrial ROS, and the PTP (Camara et al.,
2009). Indeed, recent findings indicating that
the PTP is formed by dimers of ATP synthase
will suggest that this enzyme complex may also
function as amolecular switch that signal activa-
tion of cell death pathways. The detailed mech-
anism through which this transition is achieved
are not the subject of intense study on a num-
ber of levels and will refocus the search for
pharmacological modifier of the activity of the
PTP. In terms of drugs targeting mitochon-
drial ROS, these include mitochondria-directed
antioxidants such as MitoQ and MitoVit E.
Both compounds utilize lipophilic agent TPP+
to increase uptake into mitochondria, which
has been shown to be more effective than
untargeted antioxidants in combating oxida-
tive stress (Smith et al., 1999; Adlam et al.,
2005). Another unique class of mitochondria-
targeting compounds includes the Szeto-Schiller
(SS) peptides, which have an aromatic-cationic
motif that allows them to be cell permeable
and to selectively target the intermitochondrial
membrane. Unlike MitoQ and MitoVit E, the
SS peptides do not require mitochondrial mem-
brane potential for uptake, which may be bene-
ficial when dealing with diseased mitochondria
with reduced mitochondrial membrane poten-
tials (Szeto, 2008). One of the more studied SS
peptides, SS-31, has been shown to scavenge
matrix H2O2 and ONOO−, inhibit lipid per-
oxidation, reduce mitochondrial swelling, and
reduce cytochrome c release, with notable pro-
tective effects in an amyotrophic lateral sclero-
sis (ALS) animal model as well as the MPTP
model of Parkinson’s disease (Petri et al., 2006;
Yang et al., 2009). Besides targeting mitochon-
drial ROS, another potential mitochondria-
specific target is the PTP, in particular the PTP
regulator CyPD. CyPD inhibitor CsA and its
non-immunosuppressant derivatives have been
shown to provide significant protection for
cultured neurons induced with hypoglycemic,
oxidative, and ischemic damage, as well as in
several kidney, liver, and heart disease models
(Camara et al., 2009). As for novel therapeu-
tic targets for mitochondrial preservation, the
recent work on p66 suggests that pharmaco-
logic inhibition of this ROS sensor and ampli-
fier may provide neuroprotective benefits in the
context of MS and perhaps other neurodegen-
erative diseases as well. Finally, recent advances
indicating that the PTP is formed by dimers of
ATP synthase suggest that this enzyme complex
may also function as a molecular switch that sig-
nals activation of cell death pathways (Bernardi,
2013; Giorgio et al., 2013). The detailed mech-
anism through which this transition is achieved
are now the subject of intense study on a num-
ber of levels and will refocus the search for
pharmacological modifier of the activity of the
PTP both in MS and the many other patho-
logical conditions in which the PTP plays a
significant role.
CONCLUSION
In 1868, Dr. Jean-Martin Charcot described his
examination of a young woman with a particu-
lar tremor he had never seen before. He noted
that she had other apparent neurological prob-
lems including slurred speech and abnormal eye
movements. After her death, a brain autopsy was
performed, and plaques or scleroses were noted
upon examination. Charcot termed the disease
“sclerose en plaques,” and this was the first clin-
ical description of MS (Lublin, 2005). We have
come a long way in our understanding of MS
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since Charcot first penned his description of the
disease nearly 150 years ago. We now know that
there is an immunologic component that leads
to destruction of myelin by activated immune
cells and ensuing manifestation of characteris-
tic MS symptoms. This understanding has led to
an extensive effort to develop immunomodula-
tory and immunosuppressant drugs to treat MS,
which all work at some level to combat the per-
nicious autoimmune attack on the CNS, prevent
the breakdown of the protective blood brain
barrier, and suppress the infiltration of activated
immune cells targeting myelin. Unfortunately,
these drugs, while more or less adequate in
treating relapsing-remitting MS, are unable to
treat the progressive, debilitating decline in
function that plagues a significant number of
patients. Charcot, himself, noted neuronal loss
in demyelinated lesions of MS patients, and
this pathology has been convincingly confirmed
with the aid of today’s impressive technological
tools.
While the study of neurodegenerative path-
ways in MS is still a fairly young area of
research, considerable effort has been made in
the past decade to understand the mechanisms
involved and to define potential pharmacologic
targets. Here, we have summarized some of the
extensive work done investigating the effects of
mitochondrial dysfunction on neurodegenera-
tive processes in MS, with particular emphasis
on the PTP, its modulator CyPD, and mito-
chondrial ROS sensor and amplifier p66. Thus,
MS is not a mitochondrial disease, such as
certain inherited mitochondrial diseases (e.g.,
Leber’s optic neuropathy) but we believe mito-
chondrial dysfunction is a critical component
of axonal injury within the acute focal inflam-
matory lesions and in the progressive neurode-
generative phase of the illness. It is the hope
that with continued progress in these particular
fields of research, multifaceted mitochondria-
targeted neuroprotective therapies may soon be
part of standard treatment regimen for not
only MS but other neurodegenerative diseases
as well.
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